Inventor · disambiguated record
Mark Sommerfeld
Also filed as: SOMMERFELD MARK
6 granted patents·16 pending applications·26 citations·filing 2004–2024
76Inventor score
Top patents by PatentIndex Score
22 records- 0189US10583174B2FGF21 compound / GLP-1R agonist combinations with optimized activity ratioSANOFI SA·Filed 2017·Granted Mar 10, 2020·6 cites·22 claims
- 0287US8633156B2Insulin derivatives having an extremely delayed time-action profileHABERMANN PAUL·Filed 2010·Granted Jan 21, 2014·18 cites·27 claims
- 0383US11230582B2FGF21 variantsSANOFI SA·Filed 2016·Granted Jan 25, 2022·2 cites·6 claims
- 0479US2024366727A1Fgf21 compound / glp-1r agonist combinations with optimized activity ratioSANOFI SA·Filed 2024·Application pending·0 cites
- 0577US2025171512A1Fgf21 variantsSANOFI SA·Filed 2024·Application pending·0 cites
- 0671US2022401523A1Fgf21 compound / glp-1r agonist combinations with optimized activity ratioSANOFI SA·Filed 2022·Application pending·0 cites
- 0771US2025115669A1FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic PeptidesSANOFI SA·Filed 2024·Application pending·0 cites
- 0866US2022227825A1Fgf21 variantsSANOFI SA·Filed 2021·Application pending·0 cites
- 0961US12054551B2FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptidesSANOFI SA·Filed 2021·Granted Aug 6, 2024·0 cites·14 claims
- 1060US2020261542A1Fgf21 compound / glp-1r agonist combinations with optimized activity ratioSANOFI SA·Filed 2020·Application pending·0 cites
- 1156US2018236033A1Pharmaceutical composition for treating a metabolic syndromeSANOFI SA·Filed 2018·Application pending·0 cites
- 1253US2019085043A1Fusion proteins for treating a metabolic syndromeSANOFI SA·Filed 2018·Application pending·0 cites
- 1351US2014073563A1Fusion proteins for treating a metabolic syndromeBOSCHEINEN OLIVER·Filed 2013·Application pending·0 cites
- 1450US2016279199A1Pharmaceutical composition for treating a metabolic syndromeSANOFI SA·Filed 2016·Application pending·0 cites
- 1549US2023250147A1Glp-1r agonistic peptides with reduced activitySANOFI SA·Filed 2020·Application pending·0 cites
- 1649US2013203651A1Pharmaceutical composition for treating a metabolic syndromeSOMMERFELD MARK·Filed 2011·Application pending·0 cites
- 1749US2023265152A1Glp-1r agonist / fgf21 fusion proteinsSANOFI SA·Filed 2020·Application pending·0 cites
- 1847US2015231210A1Pharmaceutical Composition for Treating a Metabolic SyndromeSANOFI SA·Filed 2015·Application pending·0 cites
- 1946US2016194371A1Fusion proteins comprising FGF-21 and GLP-1R agonistSANOFI SA·Filed 2015·Application pending·0 cites
- 2040US7803571B2Method for identifying IRS inhibitors or agonistsSANOFI AVENTIS DEUTSCHLAND·Filed 2004·Granted Sep 28, 2010·0 cites·6 claims
- 2137US2014142023A1Pharmaceutical Composition for Treating A Metabolic SyndromeSOMMERFELD MARK·Filed 2012·Application pending·0 cites
- 2235US9644017B2Insulin derivatives having an extremely delayed time-action profileHABERMANN PAUL·Filed 2010·Granted May 9, 2017·0 cites·37 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →